natgillin/translations-raw huggingface dataset:
Jentadueto 2,5 mg/1.000 mg
Jentadueto 2.5 mg/1,000 mg
Jentadueto 2,5 mg/1.000 mg filmovertrukne tabletter
Jentadueto 2.5 mg/1,000 mg film-coated tablets
Jentadueto 2,5 mg/1.000 mg filmovertrukne tabletter EU/1/12/780/015 (10 x 1 filmovertrukne tabletter)
Jentadueto 2.5 mg/1,000 mg film-coated tablets EU/1/12/780/015 (10 x 1 film-coated tablets)
Jentadueto 2,5 mg/1.000 mg filmovertrukne tabletter linagliptin/metforminhydrochlorid
Jentadueto 2.5 mg/1,000 mg film-coated tablets Linagliptin/metformin hydrochloride
Jentadueto 2,5 mg/1.000 mg tabletter indeholder også rød jernoxid (E172).
Jentadueto 2.5 mg/1,000 mg film-coated tablets also contain iron oxide red (E172).
Jentadueto 2,5 mg/1.000 mg tabletter linagliptin/metformin HCl
Jentadueto 2.5 mg/1,000 mg tablets Linagliptin/metformin HCl
Jentadueto 2,5 mg/850 mg filmovertrukne tabletter
Jentadueto 2.5 mg/850 mg film-coated tablets
Jentadueto 2,5 mg/850 mg filmovertrukne tabletter EU/1/12/780/001 (10 x 1 filmovertrukne tabletter)
Jentadueto 2.5 mg/850 mg film-coated tablets EU/1/12/780/001 (10 x 1 film-coated tablets)
Jentadueto 2,5 mg/850 mg filmovertrukne tabletter Jentadueto 2,5 mg/1.000 mg filmovertrukne tabletter
Jentadueto 2.5 mg/850 mg film-coated tablets Jentadueto 2.5 mg/1,000 mg film-coated tablets
Jentadueto 2,5 mg/850 mg filmovertrukne tabletter linagliptin/metforminhydrochlorid
Jentadueto 2.5 mg/850 mg film-coated tablets Linagliptin/metformin hydrochloride
Jentadueto 2,5 mg/850 mg tabletter indeholder også rød jernoxid (E172) og gul jernoxid (E172).
Jentadueto 2.5 mg/850 mg film-coated tablets also contain iron oxide red (E172) and iron oxide yellow (E172).
Jentadueto 2,5 mg/850 mg tabletter linagliptin/metformin HCl
Jentadueto 2.5 mg/850 mg tablets Linagliptin/metformin HCl
Jentadueto bruges alene eller sammen med andre typer lægemidler til behandling af diabetes - som f.eks. sulfonylurinstof eller insulin.
Jentadueto can be used alone or with certain other medicines for diabetes like sulphonylureas or insulin.
Jentadueto er en kombination af to antihyperglykæmiske lægemidler med komplementære virkningsmekanismer til forbedring af glykæmisk kontrol hos patienter med type 2-diabetes: linagliptin, en dipeptidylpeptidase-4-hæmmer (DPP-4), og metformin, der tilhører biguanidklassen.
Jentadueto combines two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: linagliptin, a dipeptidyl peptidase 4 (DDP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.
Jentadueto fås i perforerede enkeltdosisblistere med 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1,
Jentadueto is available in perforated unit dose blisters with 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1,
Jentadueto fås også i HDPE-beholder med plastskruelåg og silicagel (tørremiddel).
Jentadueto is also available in HDPE bottles with plastic screw cap and a silica gel desiccant.
Jentadueto hjælper med at forbedre insulinniveauet efter et måltid og nedsætter mængden af sukker, der dannes af kroppen.
This medicine helps to improve the levels of insulin after a meal and lowers the amount of sugar made by your body.
Jentadueto må ikke anvendes til patienter med type 1-diabetes eller til behandling af diabetisk ketoacidose.
Jentadueto should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Jern (som ferrimaltol)
Iron (as ferric maltol)
Jern i form af sucroferrioxyhydroxid
Iron as sucroferric oxyhydroxide
Jernafsætningen i det retikuloendoteliale system, leveren og milten blev registreret hos hunde, der fik ferrimaltol 250 mg/kg/dag.
Deposition of iron in the reticulo-endothelial system, liver and spleen was recorded in dogs adminstered 250 mg/kg/day ferric maltol.
Jernet frigives derefter intracellulært fra jern- kulhydratkomplekset i makrofagernes vesikler.
The iron is then released intracellularly from the iron-carbohydrate complex within vesicles in macrophages.
Jernindholdet bør kontrolleres hos alle patienter inden behandling for at sikre, at det ikke er for lavt, og der bør gives jerntilskud under hele behandlingen.
The iron levels of all patients should be checked before treatment to make sure that they are not too low, and iron supplements should be used throughout treatment.
Jernkoncentra- tion i lever (LIC)*
Liver iron concentration (LIC)
Jernmangel bør behandles, før behandlingen med Retacrit påbegyndes.
Iron deficiencies should be treated prior to starting treatment with Retacrit.
Jernmangelanæmi er et almindeligt problem ved kronisk tarmbetændelse.
Iron deficiency anaemia is a common problem in patients with inflammatory bowel disease.
Jernmangelanæmi, smerter i lymfeknuder, lymfadenopati, neutropeni og anæmi (begge i nogle tilfælde alvorlige), trombocytopeni
iron deficiency anaemia, lymph node pain, lymphadenopathy, neutropenia and anaemia (both occasionally severe), thrombocytopenia
Jernmåling
Iron evaluation
Jernoverskud
Iron Overload
Jernoxid (gul) E172 (kun 3 mg og 12 mg tabletter) Polyethlenoxid 7000K
Ferric Oxide (Yellow) (E172) (3, 12 mg tablet only) Polyethylene Oxide 7000K
Jernoxid (rød) (E172) Hydroxyethylcellulose Polyethylenglycol 3350 Celluloseacetat
Ferric Oxide (Red) (E172) Hydroxyethyl Cellulose Polyethylene glycol 3350 Cellulose acetate
Jernoxid (sort) (E172) (kun 1,5 mg og 9 mg tabletter)
Iron oxide (Black) (E172) (1.5, 9 mg tablet only)
Jernoxid (sort) (E172) Propylenglycol Hypromellose
Iron oxide (black) (E172) Propylene glycol Hypromellose
Jernoxid sort (E172) N-butylalkohol Renset vand Propylenglykol Ammoniumhydroxid
Iron oxide black (E172) N-butyl alcohol Purified water Propylene glycol Ammonium hydroxide
Jernoxid, gul (E 172)
Titanium dioxide (E171) Yellow iron oxide (E172)
Jernoxid, gul (E 172) Jernoxid, rød (E 172)
Titanium dioxide (E171) Iron oxide, yellow (E172) Iron oxide, red (E172)
Jernoxid, gul (E172)
Titanium dioxide (E171) Iron oxide yellow (E172)
Jernoxid, gul (E172)
Titanium dioxide (E171) Iron oxide, yellow (E172)
Jernoxid, gul (E172)
Titanium dioxide (E171) Yellow iron oxide (E172)
Jernoxid, gul (E172) Jernoxid, rød (E172)
Iron oxide, yellow (E172) Iron oxide, red (E172)
Jernoxid, gul (E172) Jernoxid, rød (E172)
Titanium dioxide (E171) Iron oxide yellow (E172) Iron oxide red (E172)
Jernoxid, gul (E172) Jernoxid, rød (E172)
Titanium dioxide (E171) Iron oxide, yellow (E172) Iron oxide, red (E172)
Jernoxid, gul (E172) Jernoxid, rød (E172) Jernoxid, sort (E172)
Titanium dioxide (E171) Iron oxide yellow (E172) Iron oxide red (E172) Iron oxide black (E172)
Jernoxid, gul (E172) Jernoxid, rød (E172) Propylenglycol
Iron oxide, yellow (E172) Iron oxide, red (E172) Propylene glycol
Jernoxid, gul (E172) Macrogol 400 Hypromellose (E464)
Titanium dioxide (E171) Iron oxide yellow (E172) Macrogol 400 Hypromellose (E464)
Jernoxid, gul (E172) Polyethylenglycol 400 Hypromellose (E464)
Titanium dioxide (E171) Ferric oxide yellow (E172) Polyethylene-glycol 400 Hypromellose (E464)
Jernoxid, gul Magnesiumstearat
Iron oxide yellow Magnesium stearate
Jernoxid, gult (E172) Jernoxid, rødt (E172)
Iron oxide yellow (E172) Iron oxide red (E172)
Jernoxid, gult (E172) Jernoxid, rødt (E172) Ethylcellulose
Titanium dioxide (E171) Iron oxide yellow (E172) Iron oxide red (E172) Ethylcellulose
Jernoxid, gult (E172) Jernoxid, rødt (E172) Vand
Titanium dioxide (E171) Iron oxide yellow (E172) Iron oxide red (E172)
Jernoxid, gult (E172) Vand
Titanium dioxide (E171) Iron oxide yellow (E172)
Jernoxid, rød (E 172) Jernoxid, gul (E 172)
Titanium dioxide (E171) Red iron oxide (E172) Yellow iron oxide (E172)
Jernoxid, rød (E172)
Titanium dioxide (E171) Red iron oxide (E172)
Jernoxid, rød (E172) Jernoxid, gul (E172)
Iron oxide red (E172) Iron oxide yellow (E172)
Jernoxid, rød (E172) Propylenglycol
Iron oxide, red (E172) Propylene glycol
Jernoxid, rød (E172) Talcum
Iron oxide red (E172) Talc
Jernoxid, rød (E172) Titandioxid (E171)
Iron oxide red (E172) Titanium dioxide (E171)
Jernoxid, rødt (E172) Vand
Titanium dioxide (E171) Iron oxide red (E172)
Jernoxid, sort (E 172)
Black iron oxide (E172)
Jernoxid, sort (E172)
Titanium dioxide (E171) Iron oxide black (E172)
Jernoxid, sort (E172) Propylenglycol
Black iron oxide (E172) Propylene glycol
Jernoxid, sort (E172) Propylenglycol Kaliumhydroxid
Iron oxide black (E172) Propylene glycol Potassium hydroxide
Jerntilskud/dolutegravir
Iron supplements/Dolutegravir
Jetrea 0,375 mg/0,3 ml injektionsvæske er en “færdigfortyndet” formel, der ikke kræver yderligere fortynding.
JETREA 0.375 mg/0.3 mL solution for injection is a ‘ready-diluted’ formulation, no further dilution is required.
Jetrea 0,375 mg/0,3 ml injektionsvæske er en “færdigfortyndet” opløsning, som ikke kræver yderligere fortynding.
JETREA 0.375 mg/0.3 mL solution for injection is a ‘ready-diluted’ formulation, no further dilution is required.
Jetrea 0,375 mg/0,3 ml injektionsvæske, opløsning
JETREA 0.375 mg/0.3 mL solution for injection
Jetrea 0,375 mg/0,3 ml injektionsvæske, opløsning ocriplasmin (ocriplasminum)
JETREA 0.375 mg/0.3 mL solution for injection ocriplasmin
Jetrea 0,5 mg/0,2 ml koncentrat til injektionsvæske, opløsning
JETREA 0.5 mg/0.2 mL concentrate for solution for injection
Jetrea er et lægemiddel, der indeholder det aktive stof ocriplasmin.
Jetrea is a medicine that contains the active substance ocriplasmin.
Jetrea klargøres til intravitreal injektion under overholdelse af følgende anvisninger:
To prepare Jetrea for intravitreal injection, adhere to the following instructions:
Jetrea klargøres til intravitreal injektion under overholdelse af følgende anvisninger: Brugsanvisning
To prepare JETREA for intravitreal injection, adhere to the following instructions:
JEVTANA 60 mg cabazitaxel som sterilt koncentrat cabazitaxel
JEVTANA 60 mg sterile concentrate cabazitaxel
JEVTANA 60 mg koncentrat og solvens til infusionsvæske, opløsning cabazitaxel
JEVTANA 60 mg concentrate and solvent for solution for infusion cabazitaxel
JEVTANA 60 mg koncentrat og solvens til infusionsvæske, opløsning.
JEVTANA 60 mg concentrate and solvent for solution for infusion.
Jevtana anvendes til behandling af mænd med hormonrefraktær metastatisk prostatakræft.
Jevtana is used to treat men with hormone refractory metastatic prostate cancer.
Jevtana anvendes, når kræften har spredt sig til andre dele af kroppen (metastatisk) og ikke længere responderer på hormonbehandling (hormonrefraktær).
Jevtana is used when the cancer has spread to other parts of the body (metastatic) and has stopped responding to hormonal treatment (hormone refractory).
Jevtana blev undersøgt i en hovedundersøgelse, som omfattede 755 mænd med hormonrefraktær metastatisk prostatakræft, der tidligere var blevet behandlet med docetaxel.
Jevtana was investigated in one main study involving 755 men with hormone refractory metastatic prostate cancer who had previously been treated with docetaxel.
Jevtana bør ikke anvendes hos personer, som kan være overfølsomme (allergiske) over for cabazitaxel, ethvert andet taxan eller et af de øvrige indholdsstoffer.
Jevtana should not be used in people who may be hypersensitive (allergic) to cabazitaxel, to any other taxane, or to any of the other ingredients.
JEVTANA er et koncentrat til infusionsvæske, opløsning (sterilt koncentrat).
JEVTANA is a concentrate and solvent for solution for infusion (sterile concentrate).
Jevtana er et lægemiddel mod kræft, der indeholder det aktive stof cabazitaxel.
Jevtana is a cancer medicine that contains the active substance cabazitaxel.
JEVTANA gives med drop (infusion) ind i en af dine vener (intravenøs brug) på hospitalet i ca. en time.
JEVTANA will be given by a drip (infusion) into one of your veins (intravenous use) in hospital for about an hour.
Jevtana gives én gang hver tredje uge som en infusion, der varer en time, med en dosis på 25 mg pr. kvadratmeter kropsoverflade (beregnet ved hjælp af patientens vægt og højde).
Jevtana is given once every three weeks as an infusion lasting one hour, at a dose of 25 mg per square metre body surface area (calculated using the patient’s weight and height).
JEVTANA i kombination med prednison eller prednisolon er indiceret til behandling af voksne patienter med hormon-refraktær metastatisk prostatacancer, der tidligere er blevet behandlet med et regime indeholdende docetaxel (se pkt.
JEVTANA in combination with prednisone or prednisolone is indicated for the treatment of adult patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen (see section 5.1).
Jevtana må udelukkende anvendes på afdelinger, der er specialiseret i kemoterapi (lægemidler til behandling af kræft), under opsyn af en læge, som har erfaring med brugen af kemoterapi.
Jevtana should only be used in units specialising in chemotherapy (medicines to treat cancer) under the supervision of a doctor experienced in the use of chemotherapy.
JEVTANA skal klargøres (fortyndes), inden det kan indgives.
JEVTANA must be prepared (diluted) before it is given.
JEVTANAs sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt.
The safety and the efficacy of JEVTANA in children and adolescents below 18 years of age have not been established.
JIA ACR30
JIA ACR 30
JIA-ACR30-flare
JIA ACR30 Flare
JIA-patienter < 30 kg
JIA patients < 30 kg
Jinarc 15 mg tabletter Jinarc 30 mg tabletter Jinarc 45 mg tabletter Jinarc 60 mg tabletter Jinarc 90 mg tabletter Tolvaptan
Jinarc 15 mg tablets Jinarc 30 mg tablets Jinarc 45 mg tablets Jinarc 60 mg tablets Jinarc 90 mg tablets Tolvaptan
Jinarc 45 mg tabletter + Jinarc 15 mg tabletter: etuier med 14 (7 tabletter i den højeste styrke +
Jinarc 45 mg tablets + Jinarc 15 mg tablets: wallet cards with 14 (7 tablets of the higher strength +
Jinarc 45 mg tabletter Jinarc 15 mg tabletter
Jinarc 15 mg tablets Jinarc 45 mg tablets
Jinarc 60 mg tabletter + Jinarc 30 mg tabletter: etuier med 14 (7 tabletter i den højeste styrke +
Jinarc 60 mg tablets + Jinarc 30 mg tablets: wallet cards with 14 (7 tablets of the higher strength +
Jinarc 60 mg tabletter Jinarc 30 mg tabletter
Jinarc 30 mg tablets Jinarc 60 mg tablets
Jinarc 90 mg tabletter + Jinarc 30 mg tabletter: etuier med 14 (7 tabletter i den højeste styrke +
Jinarc 90 mg tablets + Jinarc 30 mg tablets: wallet cards with 14 (7 tablets of the higher strength +
Jinarc 90 mg tabletter Jinarc 30 mg tabletter
Jinarc 30 mg tablets Jinarc 90 mg tablets
Jinarc er kontraindiceret under amning (se pkt.
Jinarc is contraindicated during breastfeeding (see section 4.3).
Jinarc er til brug hos patienter, der har en normal til let reduceret nyrefunktion ved begyndelsen af behandlingen med Jinarc, og hvis sygdom skrider hurtigt frem.
Jinarc is for use in patients with normal to moderately reduced kidney function at the beginning of treatment with Jinarc and whose disease is progressing rapidly.
Jinarc kan bevirke, at din lever ikke fungerer rigtigt.
Jinarc may cause your liver not to work properly.
Jinarc kan øge virkningen af ovenstående lægemidler. phenytoin eller carbamazepin (lægemidler til behandling af epilepsi), rifampicin (et lægemiddel til behandling af tuberkulose) eller prikbladet perikum (traditionel urtemedicin til lindring af let depression og angst).
Jinarc may increase the effect of these medicines. phenytoin or carbamazepine (medicines for the treatment of epilepsy), rifampicin (a medicine for treatment of tuberculosis) or St. John’s wort (a traditional herbal medicinal product for the relief of slightly low mood and mild anxiety).
Jinarc må ikke anvendes hos patienter, der ikke kan eller har svært ved at lade vandet (anuri), hos patienter med reduceret væskemængde i kroppen (volumendepletering) eller hos patienter, der ikke opfatter eller reagerer på tørst.
Jinarc must not be used in patients who are anuric (cannot pass or have difficulty in passing urine), volume depleted (have reduced amounts of fluids in the body) and in patients who cannot perceive or respond to thirst.
Jinarc skal administreres to gange dagligt i delte dosisregimer med 45 mg + 15 mg, 60 mg + 30 mg eller 90 mg + 30 mg.
Jinarc is to be administered twice daily in split dose regimens of 45 mg + 15 mg, 60 mg + 30 mg or 90 mg + 30 mg.
Jinarc tabletternes forskellige styrker har forskellige former og prægning: 15 mm tablet: blå, trekantet med “OTSUKA” og “15” på den ene side.
The different strengths of Jinarc tablets have different shapes and embossing: 15 mg tablet: blue, triangular, with “OTSUKA” and “15” on one side.
Jinarc udleveres kun efter recept, og behandlingen skal startes og overvåges af en læge med erfaring i behandling af autosomal dominant polycystisk nyresygdom og med viden om risiciene ved behandling med Jinarc.
Jinarc can only be obtained with a prescription and treatment must be started and monitored by a doctor experienced in treating autosomal dominant polycystic kidney disease and with knowledge about the risks of treatment with Jinarc.
JMEN
9.4 (8.4
JMEN: Kaplan Meier-kurver for progressionsfri overlevelse (PFS) og overlevelse (overall survival - OS) for pemetrexed versus placebo hos patienter med NSCLC bortset fra cancer hovedsageligt bestående af pladeepitelceller
JMEN: Kaplan Meier plots of progression-free survival (PFS) and overall survival pemetrexed versus placebo in patients with NSCLC other than predominantly squamous cell histology:
JMEN: Kaplan Meier-kurver for progressionsfri overlevelse (PFS) og total overlevelse (OS, overall survival).
Kaplan Meier plots of overall survival by histology
Jo flere ‘hvide aktive tabletter’ som glemmes, og jo tættere de glemte tabletter er på de 4 gule placebo-tabletter, jo større er risikoen for graviditet.
The more ‘white active tablets’ are missed and the closer the missed tablets are to the 4 yellow placebo tablets, the higher the risk of a pregnancy.
Jo højere dosis, desto mere udtalte bivirkninger.
The undesirable effects are increased with increasing dose.
Jo højere GAG- niveauerne i urin var ved baseline, desto større var faldene i GAG i urinen med idursulfase- behandling.
The higher the urinary GAG levels at baseline, the greater the magnitude of decreases in urinary GAG with idursulfase treatment.
Jo længere tid du er i behandling – især hvis du har været i behandling i mere end to år.
The longer that you are on treatment especially if you have been on treatment for more than two years.
Jodholdige kontraststoffer eller medicin, der indeholder alkohol.
iodinated contrast agents or alcohol-containing medicines
Jodsalte og/eller levothyroxin.
Iodine salts and/or levothyroxine.
Johannesurt (potent CYP3A4/5-induktor)
St John‟s wort (strong CYP3A4/5 inducer)
John's perikum (et naturlægemiddel til behandling af depression).
St John’s wort (a herbal preparation used to treat depression).
Johnson & Johnson Romania S.R.L
Johnson & Johnson Romania S.R.L.
Johnsons syndrom
Johnson syndrome
Jordbærsmag (indeholder propylenglycol)
Strawberry flavour (contains propylene glycol)
JSN-score
JSN score
juni 2017
June 2017
Juni-2016
June-2016
JuniorSTAR som giver Apidra i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Apidra in 0.5 unit dose increments
JuniorSTAR som giver doser i trin af 0,5 enheder
JuniorSTAR which delivers doses in steps of 0.5 units
JuniorSTAR som giver Insuman Basal i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Insuman Basal in 0.5 unit dose increments
JuniorSTAR som giver Insuman Comb 15 i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Insuman Comb 15 in 0.5 unit dose increments
JuniorSTAR som giver Insuman Comb 25 i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Insuman Comb 25 in 0.5 unit dose increments
JuniorSTAR som giver Insuman Comb 30 i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Insuman Comb 30 in 0.5 unit dose increments
JuniorSTAR som giver Insuman Comb 50 i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Insuman Comb 50 in 0.5 unit dose increments
JuniorSTAR som giver Insuman Rapid i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Insuman Rapid in 0.5 unit dose increments
JuniorSTAR, der giver doser i intervaller på 0,5 enheder
JuniorSTAR which delivers doses in steps of 0.5 units
JuniorSTAR, som giver Insulin Human Winthrop Basal i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Insulin Human Winthrop Basal in 0.5 unit dose increments
JuniorSTAR, som giver Insulin Human Winthrop Comb 15 i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Insulin Human Winthrop Comb 15 in 0.5 unit dose increments
JuniorSTAR, som giver Insulin Human Winthrop Comb 25 i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Insulin Human Winthrop Comb 25 in 0.5 unit dose increments
JuniorSTAR, som giver Insulin Human Winthrop Comb 30 i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Insulin Human Winthrop Comb 30 in 0.5 unit dose increments
JuniorSTAR, som giver Insulin Human Winthrop Comb 50 i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Insulin Human Winthrop Comb 50 in 0.5 unit dose increments
JuniorSTAR, som giver Insulin Human Winthrop Rapid i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Insulin Human Winthrop Rapid in 0.5 unit dose increments
JuniorSTAR, som giver Lantus i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Lantus in 0.5 unit dose increments
JuniorSTAR, som giver Toujeo i dosisintervaller på 0,5 enheder
JuniorSTAR which delivers Toujeo in 0.5 unit dose increments
Juster controlleren og lægemiddelenheden, så de passer sammen, og tryk godt ned på de to dele i begge ender.
Align the matching shapes of the controller and the drug unit and firmly press the two parts together at both ends.
Juster rillerne på hætten og tuben.
Align grooves on the cap and tube.
justere dosis af disse HMG-
HMG Co-A reductase
justeres (se pkt.
adjustment (see section 5.2).
justeres.
increased as necessary.
Justeret behandlingsforskel
Adjusted treatment
Justeret behandlingsforskel
Adjusted treatment difference
Justeret behandlingsforskel p- værdi versus placebo
Adjusted treatment difference p-value versus placebo
Justeret behandlingsforskel p-værdi versus placebo
p-value versus placebo
Justeret behandlingsforskel‡
Adjusted treatment difference
Justeret effektivitet(2)
Adjusted Effectiveness(2)
Justeret for
7.97
Justeret for
Adjusted for baseline
Justeret for anvendelse af kortikosteroider ved randomisering
Adjusted for corticosteroid use at randomisation
Justeret for baseline
Adjusted for baseline
Justeret for baseline
Baseline (mean)
Justeret for baseline 31,8* 11,1
Adjusted for baseline 31.8* 11.1
Justeret gennemsnit (95 % CI)
Adjusted mean (95 % CI)
Justeret gennemsnitlig årlig rate
Adjusted mean annual rate
Justeret hazard ratio (95 % CI)
Adjusted hazard ratio (95% CI)
Justeret hazard ratio (95% CI)
Adjusted Hazard ratio (95% CI)
Justeret Hazard ratio (HR)
Adjusted hazard ratio (HR)
Justeret infusionshastighed
Adjusted infusion rate
Justeret ændret middelværdi fra baseline
Adjusted mean change from baseline
Justeret ændret middelværdi fra baseline
Mean change from baseline
Justering af Abilify Maintena-dosis hos patienter, der samtidig tager potente CYP2D6- hæmmere, potente CYP3A4-hæmmere og/eller CYP3A4-induktorer i mere end 14 dage
Dose adjustments of Abilify Maintena in patients who are taking concomitant strong CYP2D6 inhibitors, strong CYP3A4 inhibitors, and/or CYP3A4 inducers for more than 14 days
Justering af apixabandosis er ikke nødvendig ved samtidig behandling med disse lægemidler, men hos patienter der får samtidig systemisk behandling med potente induktorer af både CYP3A4 og P-gp bør apixaban anvendes med forsigtighed til forebyggelse af apopleksi og systemisk emboli hos patienter med NVAF og til forebyggelse af recidiverende DVT og LE.
No dose adjustment for apixaban is required during concomitant therapy with such medicinal products, however in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp apixaban should be used with caution for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE.